Optimization of Infliximab Withdrawal Strategy for Rheumatoid Arthritis

Chiba University211 enrolled

Overview

This multicenter prospective clinical trial investigates the accuracy of ultrasound to predict relapse after discontinuation of infliximab and the efficacy/safety of readministration of infliximab in patients with rheumatoid arthritis in a low disease activity state.

The objective of this multicenter prospective clinical trial is to determine whether ultrasound predicts relapse after discontinuation of infliximab more accurately than does clinical index and to investigate the efficacy and safety of restarting infliximab after relapse in patients with rheumatoid arthritis in remission or low disease activity on infliximab treatment. Infliximab is discontinued in all enrolled patients. Patients are followed up for 48 weeks for monitoring relapse. If relapse occurs, patients receive readministration of infliximab and are further followed up for 24 weeks to determine the efficacy and safety of infliximab readministration. Primary endpoint is the difference in area under curve (AUC) of receiver operator characteristics (ROC) analysis between total power Doppler score and Disease Activity Score (DAS) 28 at baseline to predict relapse within 48 weeks after discontinuation of infliximab.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

211

Conditions

Arthritis, Rheumatoid

Interventions

InfliximabDRUG

Discontinue infliximab; receive Infliximab when relapse

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. 18 years or older 2. RA patients who fulfill 2010 ACR/EULAR Classification Criteria 3. Patients who have been treated with infliximab (Remicade) for 26 weeks or longer 4. DAS28 (CRP) \< 3.2 at screening 5. Patients who give written informed consent after receiving sufficient information - Exclusion Criteria: 1. Receiving prednisolone \> 10 mg/day 2. Receiving biological or molecular-target anti-rheumatic drug 3. Alteration of the dose of corticosteroid or anti-rheumatic drug within 8 weeks prior to screening visit 4. Alteration of the dose of non-steroid anti-inflammatory drug within 4 weeks prior to screening visit 5. History of infusion reaction to infliximab 6. Current infection which requires treatment 7. Current or previous demyelinating disorder 8. Current congestive heart failure which requires treatment 9. Breast-feeding or pregnant/possibly pregnant woman, or woman who does not agree to prevent conception during and 6 months after study period 10. Patients whom investigator or co-investigator consider inappropriate for other reasons -

Locations (1)

Chiba University Hospital

Chiba, Japan

Outcomes

Primary Outcomes

Area under the Receiver Operator Characteristic (ROC) curve for total power Doppler score to predict relapse

Area under the ROC curve for total power Doppler score at baseline to predict relapse within 48 weeks after discontinuation of infliximab

Time frame: 48 week

Secondary Outcomes

Area under the ROC curve for total gray-scale score to predict relapse

Area under the ROC curve for total gray-scale score at baseline to predict relapse within 48 weeks after discontinuation of infliximab

Time frame: 48 week

Change in van der Heijde modified Sharp score

Change in van der Heijde modified Sharp score at 48 week

Time frame: 48 week

Change in Health Assessment Questionnaire-Disability Index

Change in Health Assessment Questionnaire-Disability Index at 48 week

Time frame: 48 week

Change in EuroQoL 5 dimensions-5L

Change in EuroQoL 5 dimensions-5L at 48 week

Time frame: 48 week

EULAR response criteria based on DAS28 after readministration of infliximab

EULAR response criteria based on DAS28 at 12 week after relapse and readministration of infliximab

Time frame: 12 week after relapse

Number of adverse events as assessed by CTCAE v4.0

Number of adverse events as assessed by CTCAE v4.0 through study completion, an average of 60 weeks

Time frame: Through study completion, an average of 60 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.